Advances in GvHD: Current Treatments, Optimizing Prophylaxis, and Integrating Novel Therapies

Advances in GvHD: Current Treatments, Optimizing Prophylaxis, and Integrating Novel Therapies

Friday, December 4, 2020
Webinar -- 11:00 AM PT


  • Updates in Diagnostic and Prognostic Biomarkers in GvHD
  • Optimizing Prophylaxis Strategies for GvHD
  • Recent Advances in aGvHD and cGvHD Therapy


Program Director
Corey Cutler, MD

Associate Professor of Medicine
Harvard Medical School
Medical Director, Stem Cell Transplantation
Dana-Farber Cancer Institute
Boston, Massachusetts

Nelson Chao, MD, MBA

Donald D. and Elizabeth G. Cooke Professor
Chief, Division of Hematology Malignancies and Cellular Therapy/BMT
Director, Global Cancer
Duke University
Durham, North Carolina

David B. Miklos, MD, PhD

Associate Professor of Medicine
Clinical Director,
Cancer Cell Therapy Program
Division of Blood and Marrow Transplantation
Stanford University
Stanford, California

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners in treating patients with hematologic malignancies with or at risk of GvHD.

Target Audience
This program is intended for hematologists and other clinicians involved in the management of with or at risk of GvHD.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Review recent advances in our understanding of the underlying pathophysiology of GvHD and ongoing efforts to identify novel biomarkers and prognostic indicators to optimize clinical outcomes
  • Appraise the current and emerging prophylactic strategies for the prevention of GvHD
  • Evaluate available clinical trial data evaluating the use of recently FDA-approved agents and emerging treatment strategies for acute GvHD and chronic GvHD
  • Recognize adverse events and toxicities associated with prophylactic strategies and therapeutic approaches and use this information to develop supportive care plans for patients with GvHD
  • Identify patients at risk of GvHD who are candidates for ongoing clinical trials evaluating emerging options for prophylaxis and management


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.